JB Tracker-Zertifikat auf den 2012 Laggards Basket
» Report
Einige Inhalte dieser Seite sind nur für Abonnenten sichtbar.
Anmelden oder
Jetzt abonnieren!
Archiv: Alle Kategorien
Novartis new two-year data with Certican® shows positive outcomes at 24 months in largest liver transplant trial to date
» Report
SGS acquires the Ware Care Group, NL
» Report
Alpiq führt Restrukturierungsprogramm weiter
» Report
Novartis data show ACZ885 delivered rapid and strong symptom relief while reducing frequency of attacks in two periodic fever syndromes
» Report
Zehnder: Verlangsamtes Umsatzwachstum und weiterhin hohe Investitionen
» Report
Pargesa: Consolidated results 3Q 2012 (unaudited)
» Report
Ein schönes Wochenende
Joint Press Release Board of Governors of the Federal Reserve System, Federal Deposit Insurance Corporation, Office of the Comptroller of the Currency: Agencies Provide Guidance on Regulatory Capital Rulemakings
» Report
Neuemissionen ZKB Warrants
» Report
Italian authorities lift precautionary hold on Novartis seasonal influenza vaccines
» Report
IN ZEICHNUNG: JB Barrier Reverse Convertibles
» Report
CREDIT SUISSE NEW ISSUE: 8 Warrants on UBS, 4 Call(s), 4 Put(s)
» Report
UBS NEW ISSUE Stable Income & Full Upside: 5% p.a. CHF Kick-In GOAL with Participation on Nestlé, Roche, Zurich Insurance
» Report
CREDIT SUISSE NEW ISSUE: 8 Warrants on Zurich Insurance Group, 4 Call(s), 4 Put(s)
» Report
UBS issued a new 8.50% p.a. USD Early Redemption Kick-In GOAL on Worst of Nasdaq 100 / Russell 2000 / S&P 500 / S&P/TSE 60 (Valor 11406457) directly in the secondary market.
UBS issued a new 7.00% p.a. CHF Early Redemption Kick-In GOAL on Worst of Euro STOXX 50 / Nikkei 225 / SMI / S&P 500 (Valor 19946174) directly in the secondary market.
IN SUBSCRIPTION: JB Callable Multi Barrier Reverse Convertibles auf Versorger- und Goldminen-Aktien
» Report
Credit Suisse: Products in Subscription
» Report
Novartis announces update to company's Board of Directors to take effect in February 2013
» Report
